CC_65201/2024

FLUID DELIVERY DEVICE WITH TRANSCUTANEOUS ACCESS TOOL, INSERTION MECHANISM AND BLOOD GLUCOSE MONITORING FOR USE THEREWITH

InfringementCounter Claim for InfringementMilan CDCounterclaim for infringement—

Overview Decisions Reasoning Citations Documents Timeline

Parties

Claimants

Insulet Corporation

Reps: Frank Peterreins (Peterreins Schley Patent- und Rechtsanwälte)

Respondents

EOFLOW Co., Ltd.

Reps: Christopher Pierce (Hoyng Rokh Monegier)

Judges

Andrea PostiglionePresiding Judge and Judge-Rapporteur
Anna-Lena KleinLegally Qualified Judge
Uwe SchwengelbeckTechnically Qualified Judge

Patents

EP 4 201 327

CPC codes: A61M5/1723, A61M5/1452, A61M5/158, A61B5/14865, A61M5/14244, F04B9/02, A61B5/14532, A61M2230/201, A61M2005/14506, A61M5/14248, B65D83/761, A61M5/3291…

Technology area: Medical Devices · Continuous Glucose Monitoring

Sector: Packaging & Conveying

Outcome

InfringedInfringed

Filed: —

First decided: Jul 22, 2025

Language: —

The Milan Central Division issued a landmark decision finding infringement of EP 4 201 327 (Insulet Corporation) by EOFLOW Co., Ltd. by default on the counterclaim for infringement, following EOFLOW's failure to defend. The court also decided by default on the revocation action (finding insufficient grounds for revocation) and resolved costs of the preliminary injunction proceedings. The court ordered EOFLOW to cease and desist from infringing activities across all UPC contracting member states, recall products from the market, remove products from channels of commerce, destroy infringing products, and provide full information on the extent of infringement. The court applied a unitary approach to cost caps where two parallel proceedings concerned the same patent and infringement acts.

Claims

At issueall

Maintainedall

Infringedall

Notes: Milan Central Division found EOFLOW infringed EP 4 201 327 by default and dismissed EOFLOW's revocation action; patent maintained; no specific claim numbers enumerated in excerpt.